The Experimental Study On The Effect Of Erosolized Lidocaine Inhalation On Airway Inflammation In The Lungs Of Asthma Rats

Objective:To observe the effect of aerosolized lidocaine inhalation on expression of AQP5, HSP70, NF-kB and the IL-13 concentration in lungs of asthma rats model, and to study the effect of aerosolized lidocaine inhalation on the airway inflammation.Methods:Thirty two Wistar rats were randomly assigned to four groups (n=8 each): control group (group C), asthma model group (group A), dexamethasone group (group D) and lidocaine group (group L). The rats in group A were sensitized by injection of ovalbumin (OA) together with aluminum hydroxide as adjuvants, followed by aerosolized OA challenge two weeks later. The rats in group D, L were sensitized with OA as group A, but exposed to 0.02% aerosol of dexamethasone and 0.04% aerosol of lidocaine 20 minutes respectively. In group C saline was used instead of OA. Venous blood were collected to detect IL-13 concentration in 24 hours after the last challenge; the lungs were removed for microscopic examination and determination of W/D, and the expression of AQP5, HSP70, NF-kB were studied immunohistochemically.Results:Compared with the group C, The pulmonary expression of AQP5 in group A were significantly lower, but the pulmonary expression of HSP70 and NF-kB were significantly up-regulated, and the IL-13 concentration and W/D lung weight radio were significantly higher; Compared with the group A, The pulmonary expression of AQP5 in group D and L were significantly higher, the pulmonary expression of HSP70 and NF-kB were significantly down-regulated, and the IL-13 concentration and W/D lung weight radio were significantly lower. In animals with asthma the bronchial walls were significantly thicker with inflammatory cell infiltration. Dexamethasone or lidocaine aerosolized inhalation significantly attenuated the pathologic changes induced by asthma.Conclusions:Through increasing the expression of AQP5, decreasing the expression of HSP70 and NF-kB and decreasing the IL-13 concentration, aerosolized lidocaine inhalation can reduce the airway inflammation resulting from aeroallergen challenge in the asthma model of Wistar rats.